IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
TFOS is indicated for the treatment of pulmonary arterial hypertension
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Plans underway to expand screening capacity by 50% for greater accessibility
Subscribe To Our Newsletter & Stay Updated